Sagimet Biosciences
4 known investors
Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology. The company advances drug candidates through clinical trials in areas such as metabolic disease.
BiotechDigital HealthHealthtech
Founders & leadership
DH
David HappelChief Executive Officer & Director
AG
Andreas GrauerChief Medical Officer
TC
Thierry ChaucheChief Financial Officer
MO
Marie O'FarrellChief Scientific Officer
ER
Elizabeth RozekChief Legal & Administrative Officer
Investors · 4
Frequently asked questions
- What does Sagimet Biosciences do?
- Sagimet is a clinical-stage biopharmaceutical company developing therapies targeting fatty acid synthase (FASN) for metabolic diseases and oncology. The company advances drug candidates through clinical trials in areas such as metabolic disease.
- Who are Sagimet Biosciences's investors?
- Sagimet Biosciences's investors include Altium Capital, HM Venture Partners, Kleiner Perkins, New Enterprise Associates (NEA).